February 9th 2023
Eylea now also treats retinopathy of prematurity, a leading cause of childhood blindness worldwide.
January 5th 2023
January 4th 2023
December 17th 2022
October 21st 2022
FDA Uses Real-World Data to Approve Boostrix for Prevention of Infection in InfantsOctober 8th 2022
Regulators used a re-analysis of data from an observational case-control study of Tdap vaccine effectiveness to show that Boostrix given in the third-trimester prevented pertussis among infants.
Training, advising pediatricians in antibiotic usage improves compliance with prescription guidelinesJuly 4th 2013
Educating pediatricians in their offices, auditing their prescription patterns, and leveraging a shared electronic health record, encourages them to choose more appropriate antibiotics for children with common respiratory infections, according to a study published in the June 12 issue of the Journal of the American Medical Association.
Newer whooping cough vaccines less effective than older vaccinesJune 1st 2013
Teenagers who received DTaP (acellular pertussis vaccine) in their first 2 years of life had a 6 times higher risk of contracting pertussis compared with those who received DTwP (whole-cell pertussis vaccine) in their first 2 years of life, according to a study online in Pediatrics.
2012 vaccination schedules published for children, adultsMarch 1st 2012
The 2012 vaccination schedules for children, adolescents, and adults have been released, with changes to the recommendations for meningococcal and human papillomavirus (HPV) vaccinations in children and in hepatitis B vaccinations in adults.
Birth defects risk appears low with newer-generation antiepilepticsMay 27th 2011
First-trimester exposure to antiepileptic drugs compared with no exposure does not appear to increase the risk of major birth defects, according to a Danish study, published in the May 18 issue of the Journal of the American Medical Association.
Phase 3 trial finds infliximab effective in pediatric UCMay 20th 2011
Pediatric patients with moderately to severely active ulcerative colitis demonstrated a clinical response with infliximab (Remicade, Centocor Ortho Biotech), according to data from a phase 3 randomized, multicenter, open-label study.